News | July 27, 2021
GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
The company has already embarked upon significant expansion in Turkey
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
In the interim, the statutory approvals obtained by the company under SEBI ICDR have lapsed in accordance with applicable law and are required to be re-obtained
Subscribe To Our Newsletter & Stay Updated
